Seeking Alpha
21 Oct 2025, 21:41 UTC · 47w ago
Verdict
Headline takes no side. We score CELC +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Celcuity reported positive Phase 3 VIKTORIA-1 data for gedatolisib in 2nd-line PIK3CA wild type HR+/HER2- advanced breast cancer patients.
So whatPositive Phase 3 results are a primary catalyst for biotech valuation and increase the probability of regulatory approval.
More positive than 99% of claims this week
The company expects to complete a rolling NDA submission for gedatolisib by Q4 2025 under the FDA RTOR program.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 86% of claims this week
Celcuity is conducting a Phase 3 VIKTORIA-2 study to target 1st-line PIK3CA mutant and wild-type HR+/HER2- advanced breast cancer patients.
More positive than 77% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
Positive Phase 3 data and a 'Strong Buy' rating drive optimism for its drug pipeline and FDA submission.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
11h ago
+28.2%
Price agrees with the score
$84.00 vs $65.50 close before publication (Oct 21) · not market-adjusted
CELC chart →
